Home

Breast cancer drug remains on CDF after ‘significant concessions’

By 2015-07-23T14:58:00

Syringe

A breast cancer drug will remain on the list of treatments patients can access through the cancer drugs fund after the manufacturer made ‘significant concessions’ on the price.

You need to be a subscriber to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All HSJ news by sector, topic & region
  • Breaking News announcements
  • App for mobile and offline reading
  • Comment and Daily Insights newsletters
  • Regional roundup newsletters
  • 10 expert briefings every fortnight (Premium only)
  • Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant (Premium only)

Subscribe

to HSJ

Already a subscriber? Sign into your account here